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Mild asthmatic subjects experience exacerbations and are at risk of mortality. This was the 
startling revelation documented in the latest Global Initiative for Asthma (GINA) strategy 
document, which focusses largely on mild asthma.1 There are three components to consider in 
the management of asthma: control, severity and the risk of exacerbations. Asthma control 
refers to the manifestations of asthma and to the extent that they can be ameliorated by treatment. 
Severity is often assessed retrospectively by the amount and the number of medications to bring 
asthma under control; the higher the dose of the inhaled corticosteroid (ICS) and multiplicity of 
agents, the greater the severity. The risk of exacerbations is primarily influenced by the ability 
to control the disease process, that is, better symptom control diminishes the risk. However, 
other factors for increased risk include non-prescription of ICS, poor adherence and inhaler 
technique, co-morbidities, persistent allergen exposure, smoking and previous admission to an 
intensive care unit.1
To address the specific concerns of mild asthma, members of the science committee of GINA 
embarked on research studies that culminated in their recommendation that the preferred option 
is a rapid and long-acting beta 2 agonist (LABA) with concomitant ICS taken only when needed as 
the best way to obviate the risks of asthma.2,3 A critical analysis of the research that informed this 
recommendation reveals that it was in fact not the best strategy. That re-evaluation in the context 
of mild asthma and other therapeutic options that have been studied previously will be appraised.
The concept of mild, intermittent asthma
It appears incomprehensible that mild asthmatics should be subject to the major risks described 
above. In surveys including over 400 000 asthmatic subjects, the exacerbation rate amongst mild 
asthmatics (step 1 GINA) was similar to that for mild and moderate chronic persistent asthma 
(steps 2–3).4,5 In one mortality report, 33% of child deaths6 and in another given by the Royal 
College of Physicians of London,7 9% of all mortalities occurred amongst mild asthmatics. Clearly, 
a disease that puts one at risk for acute attacks and possible deaths should not be considered 
‘mild’. Thus, its severity grading should be elevated to chronic persistent, and it should get the 
appropriate treatment for that category. There are further reasons to support this stance. It has 
been well-established that patients underestimate the severity of their condition and doctors 
equally, unfortunately, do the same, putting patients into a lower severity stage than that to which 
Recognising that mild asthmatics are at risk of exacerbations and mortality, the Global Initiative 
for Asthma (GINA) issued an updated strategy in 2019. This was premised on two studies 
culminating in their recommendation that mild asthma should be treated by using a 
combination of a rapid and long-acting beta 2 agonist and an inhaled corticosteroid (ICS) 
administered as required. Their rationale is, however, debatable, as the studies actually showed 
that regular daily ICS administration was more effective for a number of asthma control 
endpoints. A patient-driven treatment strategy is also questionable, as there are a number of 
concerns about behaviour of patients suffering from asthma and perception of airway 
narrowing that should trigger medication intake but in fact does not do so. These deficiencies 
also influence a similar maintenance and reliever treatment (MART) approach that would be 
suboptimal. Intermittent ICS regimens are also inferior when compared to regular treatment. 
Not all asthmatics respond to the same dose of ICS. The best way to manage asthma is by 
adopting a step-up ICS approach, to encompass varying disease severity, with a long-acting 
beta agonist taken on a daily basis, ideally in a single combination inhaler.
Keywords: GINA 2019; mild asthma; regular ICS + LABA combination; critique.
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they belong.8,9 In addition, it has been shown that mild 
asthmatics also experience airway remodelling, especially if 
the risk factors for exacerbation (mentioned earlier) are 
present.10 This refers to the increase in the thickness of the 
sub-epithelial layer of the bronchi because of chronic airway 
inflammation. The consequence is a degree of ‘fixed 
obstruction’ (an irreversible component) as well.
It would also be expected that mild asthmatics would have 
minimal symptoms and negligible impact on their quality of 
life (QOL). However, in a large multi-country study, such 
patients, in reality, experienced significant nocturnal 
symptoms and work and activity impairment.11 The reason 
for the underassessment of the severity is related to both 
patient- and physician-related factors.9 Patients are well-
known to underplay their symptoms and impact of asthma.12 
Doctors in turn, perhaps because of limited time for 
consultations, do not assess asthma in a structured manner.9,13 
Important aspects of deficits of the impact of asthma in terms 
of both control and QOL are overlooked.
The major change in the GINA 2019 strategy is that short-
acting β2 agonists (SABA) used pro re nata (prn) are no longer 
recommended as the primary agents for episodic symptoms 
or rescue. Instead, this has been substituted by rapid-acting, 
long-acting β2 agonists (LABA-formoterol) with a steroid, 
budesonide, in a combination inhaler, to be taken only when 
symptomatic. The GINA science committee also states that 
this is the preferred recommendation. One needs to point out 
immediately that there are no data to support this regimen as 
‘preferred’ nor is there regulatory approval anywhere in the 
world for this indication. There has been no study of patient 
preferences that informed this change. Rather, the suggestion 
was informed by the two studies that were conducted and 
reported on by members of GINA themselves (Symbicort 
Given as Needed in Mild Asthma [SYGMA] 1 and 2).2,3 These 
studies enrolled mild asthmatics who had been using β2 
agonists alone or had been using low-dose ICS + SABA. They 
were then randomised to either SABA only or quick-acting 
LABA + ICS combination treatment to be taken as required or 
to a treatment involving budesonide to be taken twice daily 
(SYGMA 1 employed all three regimens whilst SYGMA 2 
utilised only the latter two options). The ICS regimens were 
superior to SABA alone for asthma control in terms of 
reduction in symptoms. Interestingly, the exacerbation rates 
improved with the ICS regimens, compared to SABA, but 
were not statistically significantly different whether taken as 
required or on a regular basis. However, asthma attacks were 
not completely abolished (see Table 1).
It must be further pointed out, that regular ICS was superior 
in a number of other outcomes and the authors of both the 
papers conceded this unequivocally! It is therefore a little 
surprising that in the GINA document, they chose the as-
needed LABA + ICS as the preferred regimen. One of 
the reasons that they rationalised was that reasonable 
(but inferior) control was acceptable because the steroid load 
would be lower (mean of 90 µg in the prn group vs. 320 µg in 
the regular group). There appears to be no credence to this 
argument as 320 µg budesonide is exceedingly safe (the 
therapeutic threshold is 800 µg beyond which systemic side 
effects are possible).14 Thus, if the patient in the regular ICS 
group exceeded this dose, one could understand the safety 
issue; at a dose ≤ 400 µg, this is not a consideration.
The multiple other benefits and superiority of regular ICS are 
shown in Table 1. The first point to be noted is the improvement 
in the pre-bronchodilator lung function. When corticosteroids 
are initiated in patients with asthma, there is an improvement 
in the pre-bronchodilator forced expiratory volume in the first 
second (FEV1).2 That is, as inflammation subsides, there is 
spontaneous bronchodilatation. This is how the efficacy of ICS 
should be monitored. Unfortunately, currently, this is usually 
difficult because many patients are already on ICS + LABA 
combinations, and the bronchodilator makes it difficult to 
check the ICS response. In SYGMA, those subjects randomised 
to prn ICS + LABA had lower pre-bronchodilator lung 
function, compared to the regular ICS group. This implies that 
airway inflammation was inadequately controlled, with the 
FEV1 difference at 1 year being approximately 55 mL. There is 
a real concern that this suboptimal control of airway 
inflammation could result in airway remodelling over time – 
fixed asthma – that simulates the spirometry seen in chronic 
obstructive pulmonary disease subjects.
Secondly, the results of the QOL questionnaires reveal that 
over 50% of subjects in the prn group had no improvements or 
worsening in the QOL. This implies that this group actually 
needed more ICS than what was prescribed. Notably, for both 
questionnaires, not a single patient in either regimen (see 
Table 1) met the criterion for a clinically important difference 
(CID) > 0.5. This again implies that higher doses of ICS were 
needed. The SYGMA studies employed fixed regimens. This is 
an old style of conducting a trial. This was commonplace over 
two decades ago during the development of ICS; for example; 
400 µg beclomethasone dipropionate would be compared to 
400 µg fluticasone propionate (FP). Superiority of the latter (as 
it is an improved ICS with better relative receptor affinity)15 
was not unexpected, but did this achieve the best clinical 
outcome, that is, what would 800 µg of FP achieve? The ICS 
equipotence trials largely ended with the landmark Gaining 
TABLE 1: A comparison of asthma control in the Symbicort Given as Needed in 
Mild Asthma studies versus Gaining Optimal Asthma Control.











% Well controlled week/
patient 
37.5 47.7 27% 80%
Annualised exacerbation/
patient 
0.14 0.15 (NS) - 0.07
ACQ: 5% of patients 
Improved 42.3 48.4 14% -
Worsened 13.7 10.3 25% -
No Change 44 41.3 - -
AQLQ: % meeting CID 0 0 - 80%
Lung function improvement: 
pre-bronchodilator
65 mL 120 mL p < 0.001 -
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; NS, not 
significant; CID, clinically important difference; GOAL, Gaining Optimal Asthma ControL; prn, 
pro re nata.
*, This is an indirect comparison.
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Optimal Asthma ControL (GOAL) study.16 For the first time, 
medication, salmeterol + FP, was up-titrated until total control 
of asthma was achieved (one of the qualifying criteria was that 
a patient would not use salbutamol at all in 7 of the previous 
8 weeks of assessment – an extremely rigorous standard). By 
way of comparison, although admittedly indirect, the stratum 
1 (ICS naïve) group of the GOAL study was compared to the 
SYGMA studies (Table 1). One notes that potentially greater 
reductions in exacerbation rates are possible, and 80% of 
patients met the CID in the QOL questionnaire.
Should inhaled steroids be used as 
needed (intermittently) or daily?
Corticosteroids exert their beneficial effects for controlling 
the disease through a number of genomic and non-genomic 
actions.17 One method to assess the efficacy of ICS is to look 
at the bronchodilator response because as has been suggested 
earlier, as inflammation decreases, the bronchi spontaneously 
dilate. In one report, 1600 µg of Budesonide was administered 
to a subject as a single dose; the Peak Expiratory Flow Rate 
(PEFR) began increasing over a few hours reaching a peak at 
8 h whereafter the PEFR began decreasing back to the 
baseline.18 In the experiment, the anti-inflammatory effect 
therefore lasted for only 8 hours. Thus, if patients only use 
ICS intermittently, there is cover for a short time and there 
may be substantial periods where there is unopposed 
inflammation in the airways. This is one of the reasons for the 
potential for exacerbations and remodelling.
Unsurprisingly, therefore, a number of studies prior to SYGMA 
have unequivocally demonstrated that intermittent ICS is 
inferior to daily ICS in both children and adults.19,20 Intermittent 
therapy results in satisfactory (but not optimal) asthma control 
and, in general, only an improvement in the PEFR. Daily ICS 
administration has been associated with a more comprehensive 
control of inflammation and improvement of:
• forced expiratory volume in the first second 
• fractional exhaled nitric oxide (FeNO) – a biomarker of 
asthmatic inflammation
• bronchial hyper-responsiveness
• percentage of eosinophils in sputum (reflecting lower 
airway allergic inflammation)
• symptom-free days
• Asthma Control Test (ACT) scores – a validated simple 
5-point questionnaire)13
• exacerbation reduction.
Another strategy to treat asthma is maintenance and reliever 
therapy (MART) that utilises a quick and long-acting ß agonist 
plus ICS in a combination inhaler.21 The patient uses a lower 
dose of baseline maintenance treatment, and when symptoms 
arise uses the same LABA + ICS product and not salbutamol. 
This protocol has been purported to provide superior control. 
However, when one studies the trials carefully, other 
observations can be made. In one trial, where MART apparently 
resulted in superior outcomes, it was noted that patients took 
an extra inhalation of the LABA + ICS product every single day 
for symptoms.22 This actually implies that patients were taking 
an extra dose of ICS daily, which was equivalent to a 50% 
increase in corticosteroid dosage, compared to the group taking 
ICS plus SABA (for relief) regularly on a daily basis; so one was 
actually comparing an overall higher ICS regimen – which 
unsurprisingly resulted in better outcomes.
Can patients be relied upon to 
adhere to pro re nata (prn) regimens?
Patient-driven treatment (MART or a SYGMA type strategy) is 
dependent on the patient perceiving symptoms and triggering 
the intake of medication. There are two problems with this 
approach. Firstly, asthmatics are quite accustomed to episodic 
chest tightness and, therefore, they often do not take treatment 
when they should.23 Secondly, this approach implies that the 
patient can accurately perceive airway closure; this is not true 
either. It has been shown that patient perception is blunted, and 
they frequently overlook decreases in airflow.21 These factors 
mean that patients will underdose themselves with the 
attendant risks. A fundamental problem with MART is that it is 
dependent on symptoms that are frequently consequent to 
increased inflammation, and thus treatment is reactive. The 
effects of these periods of heightened inflammation in 
the airways are unknown. In contradistinction, regular 
maintenance treatment is proactive, preventing instances of 
increased inflammation and potentially decreasing the 
likelihood of airway remodelling.
Global Initiative for Asthma 
recommends that salbutamol 
should not be used for 
breakthrough symptoms
Another recommendation in GINA 2019 is that when patients 
have chest tightness, salbutamol is an option, but the preferred 
reliever is again the product having the formoterol and 
budesonide combination. Once again, there is no data to 
support this strategy. One should ask if it is appropriate that 
episodic symptoms be treated with LABA + ICS instead of 
salbutamol. Salbutamol has been used for decades for acute 
relief in the chronic care of asthmatics. It provides quick relief, 
and both patients and doctors have confidence in the product. 
It is quite inexpensive, compared to an LABA + ICS inhaler – 
thus, if this were to change, it will increase healthcare costs. 
The recommendation of GINA is based on the experience of 
overreliance on SABA in treating asthma and underutilisation 
of ICS.23,24 This challenge is better solved with education 
rather than by using a much more expensive alternative.
In making the reliever option change, GINA, responding to 
patient behaviour, states that mild asthmatics would rather 
take treatment intermittently than daily. In the SYGMA studies, 
daily treatment was superior. Should we change our treatment 
strategies because of patient behaviour? Hypertensive subjects 
take medication daily in spite of the absence of symptoms 
because it represents correct management. Would we give 
diabetics medication on an intermittent basis? In asthmatics, 
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we should educate and reinforce the messages of appropriate 
treatment; intermittent treatment that is inferior is not a 
substitute for not educating patients on the correct way to 
manage their condition.
Conclusion
One should note that GINA no longer publishes guidelines but 
rather makes recommendations – a ‘strategy’ – that allow 
clinicians to review the information provided and decide on 
management issues themselves. In following the strategy, the 
severity and categorisation of asthma needs to be accurately 
defined. If asthma is truly intermittent – only very occasional 
symptoms – then SABA alone suffices. If there are more 
frequent symptoms or exacerbations, then asthma should be 
classified as chronic and persistent, and the SYGMA studies 
have shown that in this scenario daily ICSs are superior to prn 
Formoterol and Budesonide, a fact that the authors themselves 
have conceded.
One must accept that we do not have robust measures to 
assess airway inflammation, and our ability to titrate 
therapeutic interventions are at best a guess based on 
symptoms and lung function, both unreliable tools. However, 
physician-directed treatment is better than patient-driven 
treatment, as there are problems with perception of airway 
narrowing and patient behaviour in asthma, leading to 
inadequate treatment. Daily regular ICS therapy, stepping up 
in dosage dependant on disease severity with the addition 
of a LABA, has been demonstrated to regulate inflammation 
better with optimal control endpoints. Addition of the LABA 
also augments ICS activity allowing a lower ICS dose, thereby 
decreasing the steroid load.16 This is the best approach to 
prevent exacerbations and to impact the mortality related to 
asthma which are persistent global concerns.
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